NEW YORK ( TheStreet) -- Cell Therapeutics (Nasdaq: CTIC) hit a new 52-week low Wednesday as it is currently trading at $1.25, below its previous 52-week low of $1.26 with 393,889 shares traded as of 10:47 a.m. ET. Average volume has been 2.5 million shares over the past 30 days.

Cell has a market cap of $258.5 million and is part of the health care sector and drugs industry. Shares are down 42.5% year to date as of the close of trading on Tuesday.

Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer.
  • Practice your CTIC trading strategies and win cash in our stock game.

TheStreet Ratings rates Cell as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and poor profit margins. You can view the full Cell Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.